What evidence and guidelines have supported the move by oncologists toward molecular, NGS-generated mutational drivers as the optimal approach to precision cancer medicine?

What evidence and guidelines have supported the move by oncologists toward molecular, NGS-generated mutational drivers as the optimal approach to precision cancer medicine?

What evidence and guidelines have supported the move by oncologists toward molecular, NGS-generated mutational drivers as the optimal approach to precision cancer medicine?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Jinming Yu, MD, PhD

Professor Jinming Yu, MD, PhD

President, Shandong Cancer Hospital and Institute
Jinan, Shandong
China